FDA approves Bristol Myers Squibb’s Opdivo for expanded lung cancer treatment, boosting stock and investor sentiment
In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb's Opdivo ... Read More
FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced ... Read More
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq ... Read More
Study links high doses of Vitamin B supplements to increased lung cancer risk in men
A study has highlighted a significant health concern for men who consume high doses of vitamin B supplements, particularly vitamins B6 and B12. According to ... Read More
Dizal’s sunvozertinib shows promising results in global pivotal lung cancer study
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of ... Read More
Vergent Bioscience’s breakthrough at STS 2024: VGT-309 enhances lung cancer surgery
At the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024), Vergent Bioscience, a Minneapolis-based clinical-stage biotechnology company, presented compelling new data about VGT-309, ... Read More
Mirati Therapeutics secures UK approval for KRAZATI in advanced NSCLC
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its ... Read More
Lilly’s Retevmo outperforms in trials for RET fusion-positive NSCLC and RET-mutant MTC
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with ... Read More
ENHERTU receives EU approval for advanced non-small cell lung cancer
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) ... Read More
Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal
Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More